Vandetanib (Figure 3), a selective inhibitor of VEGFR2, is an orally bioavailable 4-anilinoquinazoline that has been reported to induce anti-tumor activity through downregulating the expression of the VEGFR gene, inhibiting angiogenesis, and inducing TNBC cell necrosis. This evidence concerns the gene KDR and neoplasm.